Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
Ionis will present new analyses from its pivotal Phase 3 CORE and CORE2 studies for olezarsen at three major medical conferences in June. The presentations cover insights into patients with diabetes, pancreatitis risk across triglyceride levels, and efficacy in patients with versus without baseline fibrate use.
Key figures
- Drug Name
- olezarsen
- Phase Of Trial
- Phase 3
- Fda action date
- June 30, 2026
- Us patients shtg
- 3 million
- Us high risk patients
- 1 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.